Democritus University of Thrace (DUTH)
Φαρμακολογική μελέτη των υποδοχέων του εκλυτικού παράγοντα κορτικοτροπίνης ως θεραπευτικών στόχων σε περιφερικά συστήματα και στον καρκίνο
Abstract
dc:descriptionThe Corticotropin Releasing Factor system has been characterized as the main regulator of the body's endocrine, behavioral and autonomic responses to stress, maintaining homeostasis at these levels. The CRF system, in addition to the hypothalamic neuropeptide CRF, consists of its homologous peptides, Urocortins (Ucn) I, II, and III, the two types of receptors CRF-R1 and CRF-R2, and the binding protein CRF- BP. The two receptors (CRF-Rs), which present different distribution and functions, both belong to class B of G-protein coupled receptors (GPCRs). The CRF system is located in many areas of the CNS which are involved in stress response actions. In each cell type, activation of the conjugated G-proteins leads to activation of multiple and different signaling pathways (such as the cAMP-PKA pathway, the PKC pathway, the ERK-MAPK pathway, the Akt / Protein Kinase B-PI- 3 pathway, the NF-κB, Nur1 / Nur77 signaling pathway, as well as other transcription factor-mediated signaling pathways). The selective binding of the CRF neuropeptides to the CRF-R subtypes leads to tissue specific signaling. The CRF ligand-receptor system is also extended to the periphery where it acts independently affecting a variety of cell types. It appears to hold multiple physiological regulatory roles and it is possible to be involved in stress-related pathogenic mechanisms. Furthermore, the CRF system has been shown to be involved in the regulation of the cell cycle and inflammation. In recent years, many studies have shown the association of the CRF system with various types of cancer. Based on studies using in vitro experimental models, the CRF neuropeptide family and its receptors have been suggested to be involved in the regulation of human cancinogenesis, metastasis, angiogenesis and immune escape of various malignancies. Μany studies provide scientific information regarding CRF system expression in a wide range of human malignancies, while further clarification of its biological role is essential in order to support the pathophysiological significance of these findings. Along with many others, our research team has published data providing evidence that both receptors of the CRF system are expressed in human breast cancer cells - derived either from breast cancer tumor biopsies or from experimental in vitro models of breast cancer cells - showing distinct distribution and transduction activity. These results point into their biological role in the development, homeostasis and migration capacity of breast cancer cells. The purpose of the present study was the investigation of CRF receptor expression and signaling in breast cancer and the understanding of the molecular mechanisms involved in the actions of the system in the periphery, specifically in carcinogenesis, and approaching them as potential therapeutic targets. It is an in vitro study, which started with the characterization of the MCF-7 human cancer cell line as a model for the CRF system in breast cancer. We first described the expression of the CRF receptors at the gene and protein levels, by the Reverse Transcription quantitative PCR (RT qPCR) and immunofluorescence (IF) respectively, under basal and hormone dependent conditions. Expression of CRF-R2 was detected in the MCF-7 cell membrane by immunofluorescence, whereas RT qPCR showed gene expression of both types of receptors, with CRF-R2a receptor being the major sybtype expressed. The regulation of CRF-Rs transcription in MCF-7 cells by estrogens (E2) was found opposite for the two CRF-Rs: it was noticed that CRF-R1 expression was increased, while CRF-R2 mRNA was decreased. Following, in order to understand the mechanism and regulation level of gene expression of CRF-R1 and CRF-R2, a study was performed on the methylation status of the gene promoters. Another interesting finding was the statistically significant demethylation of CRF-R1 promoter under treatment with the demethylating agent 5-AZA-CR, while no effect was noticed on the methylation status of the CRF-R2, demonstrating different regulation levels of gene expression. Under E2 treatment, no effect was noticed on the methylation status of both receptors. The results from the cancer cell line were evaluated in parallel with measurements in a panel of human breast cancer biopsies, where CRF-R1 methylation was significantly increased in human breast cancer biopsies samples positive for ER and / or PR expression. Furthermore, selective cell signaling was investigated in relation to growth parameters (cell proliferation, migration potential) of the cancer cell line MCF-7, and their interaction to hormonal induction. For these experiments, a system that monitors the cellular behavior through real-time measurements was used. Time and dose- dependent effects of the CRF system agonists or antagonists were evaluated. Regarding CRF-R2 in vitro activation, the specific and selective agonist UcnII was chosen. Cell proliferation assays in MCF-7 cells showed no effect of UcnII on cell growth under basal or E2- dependent induction. On the other hand, migration assays devealed a noticeable increase on the migration potential of MCF-7 cells under UcnII. The effect was abolished by the selective CRF-R2 antagonist, Astressin-2B, demonstrating the specific activation of the CRF-R2. Finally, the addition of UcnII in the E2-conditioned medium potentiated the migration potential of MCF-7 cells. Our data demonstrate an active "dialogue" between the CRF system and steroid hormones in breast cancer. Its elucidation may contribute to a complete picture of the complex molecular events which are involved in the hormone-dependent breast carcinogenesis and may contribute to the identification of new therapeutic targets.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koureta, Maria
- Κουρέτα, Μαρία
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47482